Kenvue Inc. $KVUE Shares Sold by Childress Capital Advisors LLC

Childress Capital Advisors LLC decreased its stake in Kenvue Inc. (NYSE:KVUE) by 4.3% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 14,541 shares of the company’s stock after selling 647 shares during the period. Childress Capital Advisors LLC’s holdings in Kenvue were worth $304,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Cambridge Investment Research Advisors Inc. boosted its stake in Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock valued at $2,545,000 after acquiring an additional 4,034 shares in the last quarter. Renaissance Capital LLC boosted its stake in Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after acquiring an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Kenvue by 80.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after purchasing an additional 16,164 shares during the period. Arlington Partners LLC acquired a new stake in shares of Kenvue in the 2nd quarter valued at about $2,110,000. Finally, IFP Advisors Inc boosted its position in shares of Kenvue by 25.3% in the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock valued at $369,000 after purchasing an additional 3,081 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $15.88 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The stock has a fifty day moving average price of $19.99 and a 200 day moving average price of $21.68. Kenvue Inc. has a 1-year low of $15.82 and a 1-year high of $25.17. The company has a market cap of $30.47 billion, a PE ratio of 21.45, a P/E/G ratio of 2.33 and a beta of 0.73.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter last year, the business earned $0.32 EPS. The business’s revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a yield of 5.2%. Kenvue’s payout ratio is 112.16%.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Redburn Partners set a $22.00 target price on Kenvue in a research report on Friday, September 26th. Royal Bank Of Canada decreased their price objective on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a report on Friday, August 8th. Bank of America decreased their price target on shares of Kenvue from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, July 15th. Barclays decreased their price target on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, JPMorgan Chase & Co. decreased their price target on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $22.73.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.